Articles
Tunnah’s musings: Syrum - saving the world or saving pharma?

Tunnah’s musings: Syrum - saving the world or saving pharma?

Paul Tunnah’s latest musings neatly coincides with the beta launch of Boehringer’s new Facebook game Syrum, as he asks John Pugh what it might do for pharma. It’s probably fair to say that the words ‘pharma’ and ‘glitz’ do not often go hand in hand. However, Boehringer Ingelheim’s John Pugh certainly managed to inject …

Articles
External perspectives: key account management

External perspectives: key account management

In a new series where we hear from people who work within industries outside of pharma, we speak with Hajo Rapp on how Siemens has successfully implemented key account management. Last year, Siemens AG was recognised by the Strategic Account Management Association (SAMA) for its successful customer management...

Articles
Redefining the blockbuster model: Why the $1 billion entry point is no longer sufficient - part 1

Redefining the blockbuster model: Why the $1 billion entry p...

In the first of a two-part article, Sarah Rickwood questions how, with so many ‘blockbuster drugs’ we can truly define an outstanding pharmaceutical product. When Zantac® surpassed US$1 billion in annual sales in 1987, the first global “blockbuster” pharmaceutical product was born. Today...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. ESMO26: Tango sees 82% ORR with combo in pancreatic cancer
  2. Roche offers $15bn for strategic-level deal with Hansoh
  3. ESMO26: Moderna, MSD reveal cancer jab data early after leak
  4. Clinical trial setup times fall sharply in UK
  5. Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more